Epigenetic Regulation in Overcoming Chemoresistance

·
· Cancer Sensitizing Agents for Chemotherapy ຫົວທີ 16 · Academic Press
ປຶ້ມອີບຸກ
144
ໜ້າ
ມີສິດ
ບໍ່ໄດ້ຢັ້ງຢືນການຈັດອັນດັບ ແລະ ຄຳຕິຊົມ ສຶກສາເພີ່ມເຕີມ

ກ່ຽວກັບປຶ້ມ e-book ນີ້

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. - Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult - Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials - Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

ກ່ຽວກັບຜູ້ຂຽນ

Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program, and the “National Natural Science Foundation. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.Chunfu Wu,PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program, and the “National Natural Science Foundation. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.

Lihui Wang, PhD, obtained his PhD in Pharmacology from Shenyang Pharmaceutical University in 2006. After that, Dr Wang started his investigation in the same institute, where he was promoted to full professor in 2018. From 2016 spring to 2017 summer, Dr. Wang majors in anti-cancer drug researches and went to Memorial Sloan Kettering Cancer Center in New York as a visiting investigator. Dr. Wang has published more than 20 papers, as first or corresponding author, in international peer reviewed journals, and his research focus is anti-cancer drugs development and chemo-sensitization.

ໃຫ້ຄະແນນ e-book ນີ້

ບອກພວກເຮົາວ່າທ່ານຄິດແນວໃດ.

ອ່ານ​ຂໍ້​ມູນ​ຂ່າວ​ສານ

ສະມາດໂຟນ ແລະ ແທັບເລັດ
ຕິດຕັ້ງ ແອັບ Google Play Books ສຳລັບ Android ແລະ iPad/iPhone. ມັນຊິ້ງຂໍ້ມູນໂດຍອັດຕະໂນມັດກັບບັນຊີຂອງທ່ານ ແລະ ອະນຸຍາດໃຫ້ທ່ານອ່ານທາງອອນລາຍ ຫຼື ແບບອອບລາຍໄດ້ ບໍ່ວ່າທ່ານຈະຢູ່ໃສ.
ແລັບທັອບ ແລະ ຄອມພິວເຕີ
ທ່ານສາມາດຟັງປຶ້ມສຽງທີ່ຊື້ໃນ Google Play ໂດຍໃຊ້ໂປຣແກຣມທ່ອງເວັບຂອງຄອມພິວເຕີຂອງທ່ານໄດ້.
eReaders ແລະອຸປະກອນອື່ນໆ
ເພື່ອອ່ານໃນອຸປະກອນ e-ink ເຊັ່ນ: Kobo eReader, ທ່ານຈຳເປັນຕ້ອງດາວໂຫຼດໄຟລ໌ ແລະ ໂອນຍ້າຍມັນໄປໃສ່ອຸປະກອນຂອງທ່ານກ່ອນ. ປະຕິບັດຕາມຄຳແນະນຳລະອຽດຂອງ ສູນຊ່ວຍເຫຼືອ ເພື່ອໂອນຍ້າຍໄຟລ໌ໄໃສ່ eReader ທີ່ຮອງຮັບ.